Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

The Effects of Beta-Alanine Supplementation on Mechanical Performance, Acid-Base Balance, Oxidative Stress, and Enzymatic Antioxidant Defence During Repeated Wingate Anaerobic Tests Under Normoxic and Hypoxic Conditions

15 de junho de 2026 atualizado por: Mateusz Gawełczyk, The Jerzy Kukuczka Academy of Physical Education in Katowice

Beta-alanine is a dietary supplement that increases skeletal muscle carnosine concentration and may enhance the muscle's ability to buffer hydrogen ions produced during high-intensity exercise. This buffering effect could potentially delay fatigue and improve exercise performance, particularly under conditions that increase metabolic stress, such as hypoxia. However, previous studies examining the effects of beta-alanine supplementation on repeated sprint performance under hypoxic conditions have produced inconsistent findings.

The purpose of this study is to determine whether four weeks of beta-alanine supplementation improves repeated high-intensity cycling performance and influences markers of acid-base balance in trained male cyclists exercising under normoxic and hypoxic conditions. Participants will perform repeated Wingate anaerobic cycling tests before and after a four-week supplementation period with either beta-alanine or placebo.

Mechanical performance outcomes, including peak power, mean power, total work, and fatigue indices, will be assessed alongside physiological measures of metabolic stress, including blood lactate concentration, pH, bicarbonate concentration, and base excess. Performance and physiological responses will be compared between supplementation groups and environmental conditions.

The findings of this study may contribute to a better understanding of the ergogenic potential of beta-alanine supplementation during repeated high-intensity exercise and provide practical information for athletes and practitioners regarding the effectiveness of beta-alanine under conditions of reduced oxygen availability.

Visão geral do estudo

Descrição detalhada

Beta-alanine is a non-essential amino acid and the rate-limiting precursor for the synthesis of carnosine, an intracellular dipeptide found in high concentrations within skeletal muscle. Carnosine contributes to intracellular acid-base regulation by buffering hydrogen ions (H+) produced during high-intensity exercise. Supplementation with beta-alanine has consistently been shown to increase muscle carnosine concentrations, potentially enhancing buffering capacity and delaying the onset of fatigue during exercise characterized by substantial glycolytic energy production.

The ergogenic potential of beta-alanine has been extensively investigated in a variety of exercise modalities. Previous studies and meta-analyses suggest that supplementation may improve performance during high-intensity exercise lasting approximately one to four minutes, where metabolic acidosis is considered an important contributor to fatigue. However, findings remain inconsistent, particularly in exercise protocols involving repeated maximal efforts and in environmental conditions that alter oxygen availability.

Exercise performed in hypoxic environments is associated with reduced oxygen delivery to working muscles, increased reliance on anaerobic glycolysis, accelerated accumulation of hydrogen ions and lactate, and greater disturbance of acid-base homeostasis. Consequently, hypoxic exercise may increase the physiological importance of buffering mechanisms and potentially enhance the relevance of interventions aimed at improving buffering capacity. Despite this theoretical rationale, limited information is available regarding the effectiveness of beta-alanine supplementation during repeated supramaximal exercise performed under hypoxic conditions.

The purpose of this study is to evaluate the effects of four weeks of beta-alanine supplementation on repeated high-intensity cycling performance and physiological responses associated with metabolic acidosis in trained male cyclists. The study utilizes a randomized, double-blind, placebo-controlled design. Participants complete repeated laboratory testing sessions under both normoxic and normobaric hypoxic conditions before and after the supplementation period.

Exercise performance is assessed using a repeated Wingate anaerobic cycling protocol consisting of three consecutive 30-second maximal efforts separated by standardized recovery intervals. The protocol was selected because it induces substantial anaerobic energy production and metabolic stress, allowing evaluation of both performance outcomes and buffering-related physiological responses. Testing is conducted under normoxic conditions and under normobaric hypoxia corresponding to an altitude of approximately 2500 meters above sea level.

Physiological measurements include assessments of blood lactate concentration and indicators of acid-base balance collected in conjunction with the exercise protocol. These measurements are intended to characterize the metabolic and buffering responses to repeated supramaximal exercise and to determine whether beta-alanine supplementation modifies these responses.

The study is designed to improve understanding of the role of beta-alanine supplementation in athletes performing repeated high-intensity exercise under conditions of normal and reduced oxygen availability. The findings may contribute to the evidence base regarding nutritional strategies intended to support performance during repeated maximal efforts and may help clarify whether environmental stressors such as hypoxia influence the ergogenic effectiveness of beta-alanine supplementation.

Tipo de estudo

Intervencional

Inscrição (Real)

38

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Katowice, Polônia
        • Academy of Physical Education in Katowice

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto

Aceita Voluntários Saudáveis

Sim

Descrição

Inclusion Criteria:

  • Healthy male participants aged 20-50 years
  • Regularly riding a bike (min. 5000 km on the bike in the last year)
  • Willingness to maintain habitual dietary and physical activity patterns throughout the study.
  • Willingness to refrain from consuming dietary supplements other than those provided as part of the study.

Exclusion Criteria:

  • Prevalence of chronic diseases
  • β-alanine supplementation within the previous six months
  • Use of other dietary supplements, except carbohydrate and whey protein supplements
  • Adherence to a vegetarian or vegan diet
  • Participation in another clinical trial within the previous 3 months.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Ciência básica
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição fatorial
  • Mascaramento: Triplo

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: BA-N
Beta-alanine + normoxia
β-alanine (6 g·day-¹)
Outros nomes:
  • BA
normoxic conditions
Outros nomes:
  • N
Comparador de Placebo: PL-N
Placebo + normoxia
normoxic conditions
Outros nomes:
  • N
Placebo (6 g·day-¹)
Experimental: BA-H
Beta-alanine + hypoxia
β-alanine (6 g·day-¹)
Outros nomes:
  • BA
Normobaric hypoxic conditions (≈2500 m)
Outros nomes:
  • H
Experimental: PL-H
Placebo + hypoxia
Placebo (6 g·day-¹)
Normobaric hypoxic conditions (≈2500 m)
Outros nomes:
  • H

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Prazo
Mean Power (W)
Prazo: 4 weeks
4 weeks

Medidas de resultados secundários

Medida de resultado
Prazo
Peak Power (W)
Prazo: 4 weeks
4 weeks
Relative Peak Power (W·kg-¹)
Prazo: 4 weeks
4 weeks
Total Work (J)
Prazo: 4 weeks
4 weeks
Fatigue Slope (W·s-¹)
Prazo: 4 weeks
4 weeks
Rate of Fatigue (%)
Prazo: 4 weeks
4 weeks
Time to Peak Power (s)
Prazo: 4 weeks
4 weeks
minimum power (MinP)
Prazo: 4 weeks
4 weeks
Lactate (mmol·L-¹)
Prazo: 4 weeks
4 weeks
pH
Prazo: 4 weeks
4 weeks
BE(B) (mmol·L-¹)
Prazo: 4 weeks
4 weeks
HCO₃- (mmol·L-¹)
Prazo: 4 weeks
4 weeks

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Diretor de estudo: Mateusz Gawelczyk, PhD, Institute of Sport Sciences, Academy of Physical Education, 40-065 Katowice, Poland

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

20 de novembro de 2019

Conclusão Primária (Real)

1 de junho de 2026

Conclusão do estudo (Real)

1 de junho de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

10 de junho de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

10 de junho de 2026

Primeira postagem (Real)

16 de junho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

17 de junho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

15 de junho de 2026

Última verificação

1 de junho de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Anonymised data will be available upon reasonable request.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever